Literature DB >> 10870658

Prevalence of pulmonary disorders in patients with newly diagnosed rheumatoid arthritis.

J J Doyle1, A H Eliasson, G J Argyros, G J Dennis, D R Finger, K M Hurwitz, Y Y Phillips.   

Abstract

Our objective was to determine the prevalence of airway hyperreactivity (AHR) in patients with newly diagnosed rheumatoid arthritis (RA) who had received no disease-modifying antirheumatic drugs (DMARDs) and to characterise the spectrum of lung diseases identifiable in these patients at the time of presentation. Eighteen consecutive patients with newly diagnosed RA referred to our medical centre's rheumatology clinic over 2 years underwent pulmonary evaluation with arterial blood gas analysis, chest radiographs, spirometry before and after bronchodilator medication, and body plethysmography. They returned on subsequent days in random order for methacholine inhalation challenge (MIC) and eucapnic voluntary hyperventilation (EVH) as bronchoprovocation techniques. One patient had severe obstructive disease at presentation and therefore did not undergo bronchoprovocation. We found a wide variety of pulmonary abnormalities, including two patients with hypoxia (12%), two with obstruction (12%), three with restriction (18%) and four with AHR (23%). The data also suggest a strong association between pulmonary diseases in RA and cigarette smoking. Although no single characteristic lung disease such as AHR was identified in patients presenting with RA, the association between lung disease and cigarette smoking is striking and underscores the need to emphasise smoking cessation in this patient population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10870658     DOI: 10.1007/s100670050160

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

1.  Outcome of patients with connective tissue disease requiring intensive care for respiratory failure.

Authors:  Jinwoo Lee; Jae-Joon Yim; Seok-Chul Yang; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Eun Young Lee; Eun Bong Lee; Yeong Wook Song; Sang-Min Lee
Journal:  Rheumatol Int       Date:  2011-09-27       Impact factor: 2.631

Review 2.  Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology.

Authors:  Emily K Wu; Robert D Ambrosini; R Matthew Kottmann; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi
Journal:  Curr Rheumatol Rev       Date:  2019

3.  Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Authors:  Jorge A Zamora-Legoff; Megan L Krause; Cynthia S Crowson; Jay H Ryu; Eric L Matteson
Journal:  Arthritis Rheumatol       Date:  2017-03       Impact factor: 10.995

4.  Patterns of interstitial lung disease and mortality in rheumatoid arthritis.

Authors:  Jorge A Zamora-Legoff; Megan L Krause; Cynthia S Crowson; Jay H Ryu; Eric L Matteson
Journal:  Rheumatology (Oxford)       Date:  2017-03-01       Impact factor: 7.580

5.  Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease.

Authors:  Jorge A Zamora-Legoff; Megan L Krause; Cynthia S Crowson; Jay H Ryu; Eric L Matteson
Journal:  Clin Rheumatol       Date:  2016-07-22       Impact factor: 2.980

6.  Does practice mirror the evidence base in the treatment of rheumatoid arthritis?

Authors:  Iain McInnes
Journal:  Clin Rheumatol       Date:  2009-05-13       Impact factor: 2.980

7.  Longitudinal micro-CT as an outcome measure of interstitial lung disease in TNF-transgenic mice.

Authors:  Richard D Bell; Christopher Rudmann; Ronald W Wood; Edward M Schwarz; Homaira Rahimi
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

Review 8.  Interstitial lung disease throughout the rheumatoid arthritis disease course.

Authors:  Gregory C McDermott; Tracy J Doyle; Jeffrey A Sparks
Journal:  Curr Opin Rheumatol       Date:  2021-05-01       Impact factor: 5.006

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.